COVID-19: Diagnosis and Cure - Review

Bhupendra Prasad

Microbiology Career College Bhopal, India.

DOI: 10.38177/ajast.2020.4212

Abstract

In 2019 COVID-19 (novel coronavirus disease) declared as a global health emergency. It is firstly reported in Wuhan, China. 11 February, 2020, the approximate number of confirmed cases in China has reached 38 800, with 4740 (12.2%) cured cases and 1113 (2.9%) deaths. After that COVID-19 creates a worldwide threaten with a huge number of deaths. Developed countries like USA, Italy, united Kingdom etc., all are affected with COVID-19. There is no vaccine is reported till dated for COVID-19, only precautions and social distancing is the solution of this problem. Many diagnosis methods are used to detect COVID-19 positive numbers like Ground-glass and consolidative opacities with Computed Tomography scan, Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) assay, Real time polymerase chain reaction (RT PCR), Antigen ELISA. Many Scientist and medical workers try to get the solution of this infectious communicable disease. There are many treatment methods to cure this syndrome which are included here. This review has collective information about diagnosis and cure methods with current researches on Coronavirus and COVID-19.

Keywords: COVID-19, RT-PCR, ELISA, CT Scan, RT qPCR.

Introduction

Start with the history of human coronavirus, the first evidence was seen in 1965 when Tyrrell and Bynoe. It is present in human embryonic tracheal organ cultures isolated from the respiratory tract of an adult with a common cold. In the late 1960s, Tyrrell was developed leading group of virologists, they work on many human strains and an animal viruses. All the viruses was examined morphologically by electron microscope, here they get a new group of viruses known as corona virus (It showing the crown like appearance with their surface protein so name as corona) (5). In 2003 SARS corona virus (SARS-CoV) is explored in an animals, perhaps bats, civet cats. In China 2002 first infected human was found in Guangdong province declared by world health organization. On 31 December 2019 first unknown pneumonia case in Wuhan and reported to WHO office in china. 30 January 2020 WHO declared it as a public Health Emergency for entire world and after a research named as COVID-19 a novel corona virus. As per current status by WHO at 1 June 2020 number of infected person are given in the table 1.

| S.No. | Regions                     | Confirmed cases | Deaths   |
|------|-----------------------------|-----------------|----------|
| 1    | European Region             | 2 159 791       | 180 594  |
| 2    | Region of the Americas      | 2 817 232       | 160 514  |
| 3    | Western Pacific Region      | 183 198         | 7 037    |
| 4    | Eastern Mediterranean Region| 520 137         | 12 627   |
| 5    | South-East Asia Region      | 272 512         | 7 743    |
| 6    | African Region              | 104 242         | 2 638    |

Indian current situation report by WHO on 31 May 2020 are 182,143 COVID19 cases, and 5,164 deaths.
About Corona virus: Corona belongs to largest group of viruses of order Nidovirales. Alpha, beta, gamma and delta are the four subgroup of corona virinae. It is highly communicable due to the presence of S protein present in receptor binding domains (RBD) (6). Life cycle is given in table 1.

Diagnostic methods

Ground-glass & consolidative opacities with CT scan. One of the methods used for diagnosis in radiology is a Ground-glass and consolidative opacities with CT scan indicate in lungs filled with air spaces and partial collapse of lungs alveoli.(7) It is commonly associated with lungs disorder like lungs inflammation or infiltrative. Ground-glass opacities having selected features to give more accurate and predictive results followed by computed tomography. Many researchers give the statistical numbers about the patients diagnosed with this method.(8) Radiologist perform a crucial role for early investigation of novel corona virus (COVID-19) computed tomography findings. It is also helpful in recognizing other diseases like viral pneumonia with similar viral family like SARS and MERS (1).

Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR).

Many types of SARS-COV-2 nucleic acid test kit have been evolved and authorized quickly, with the time; ‘suspected’ cases were increased with standard clinical COVID-19 attributes and identical particular computed tomography (CT) images were not diagnosed. Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) assay has method been used for the detection of causative viruses from respiratory discharge and the end pathogenic diagnostics of COVID-19. Unluckily, due to massive situation in local hospitals, many diagnosed cases and ‘suspected’ cases couldn’t systematically be separated or treated. Newly, one patient wasn’t confirmed by RT-qPCR testing for SARS-COV-2 infection for the first three times within 3 weeks before 3 weeks before bronchoalveolar lavage fluid (BALF) was obtained, results from RT-qPCR testing was positive for SARS-COV-2. Overall conditions were coherence to control viral extending and breakout. For example, results from RT-qPCR testing using primers in ORF1ab genes and N genes can be infected by modification of viral RNA sequences (2).

Real time reverse-transcription-polymerase-chain-reaction (RT-PCR).

The real time reverse-transcription-polymerase-chain-reaction (RT-PCR) assay has been progressed and used in clinics for COVID-19. RT-PCR remains as the standard reference to make a positive diagnose of COVID-19 infection, the false negative rate (FNR) increases and unavailability of RT-PCR assay in the initial stage of the breakout controlled and early diagnosis of infected patients. RT-PCR positive for COVID-19 remains the common reference. Still, RT-PCR results can be changed by low virus load and sampling errors. Earlier studies about SARS
revealed that RT-PCR deficits sensitivity during the initial five days of the disease. Recent information indicates that chest CT may signify pneumonia but multiple RT-PCR of nasopharyngeal or throat swabs test negative. Moreover, RT-PCR results must be scanned by the Centers for Disease Control and Prevention (CDC) in the initial stage of breakout, taking a prolong time to confirm the final diagnosis (3).

**Antigen ELISA.**

It is also one of the diagnostic methods for detection of corona. Commercially this assay is work on two immunoglobulin’s IgG and IgA and shows higher sensitivity with IgA. There are two major structural protein of corona viruses is major problem are spike (S) for attachment and nucleo-capsid (N) immugens. Antigen ELISA is a serological assay for virus neutralizing antibodies, antibodies against N protein, S protein and receptor binding domain (RBD) in serum samples of PCR confirmed SARS-CoV-2. In this study antigen ELISA plays a key role for sero-surveillance studies and evaluation of vaccine trials (4).

### Table 2: Comparison of different diagnosis methods

| Types of diagnostic tests | Specific tests by CT (computed tomography) | Immunoassay | Molecular test by PCR (polymerase chain reaction) |
|--------------------------|-------------------------------------------|-------------|--------------------------------------------------|
|                          | **Detect symptoms and signs of disease**   | Antigen based | Detect the existence of viral genetic material in a sample |
|                          | **Antibody based**                        |             |                                                   |
|                          | **Detects the existence of anti-viral antibodies in** |             |                                                   |
|                          | **Antigen based**                         |             |                                                   |
|                          | **Detects the presence of viral proteins (antigens) in a sample** |             |                                                   |
| What technique is used?  | Techniques comprises thermal scanning to identify person with a fever (higher than normal temperature) and computed tomography (CT) chest scans to differentiate from other chest infections | Commonly based on a technique called enzyme linked immunosorbent assay (ELISA), in which molecules merge to the antibodies or antigen in the sample and produce a detectable signal | Commonly bases on a technique called polymerase chain reaction (PCR), which makes millions of copies of a particular section of the viral genome, amplifying least amounts to detectable levels. |
| Where does testing take | Commonly performed outside                 | Might be laboratory based or performed at point of care, depending on test design | Commonly performed in a laboratory due to |


| What is the most common use? | Triage/screening to find candidates for advance testing | Examine overall infection and immunity rates in a community | Testing people suspected of having COVID-19 or triage/screening to find candidates for advance testing (assessing on test design) | Testing people suspected of having COVID-19 |
|-------------------------------|--------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------|
| A positive result...          | Proposes a potential infection and suggests that advance testing is needed. | Shows a current or past infection, and screen for may be used to current infection | Confirms a current SARS-CoV-2 infection or suggests a potential infection (depending on test design) | Suggests a potential infection and indicates that further testing is needed |

**Curative methods**

As we all know the novel coronavirus disease 2019 (COVID-19) is spreading rapidly and the most effective cure is social distancing. Chloroquine phosphate is an old drug used for malaria treatment and it is also effective for pneumonia caused by COVID-19. Chloroquine showing broad-spectrum antiviral activities, it increase endosomal pH which is required for virus fusion (9). Other than chloroquine and some other drugs are in clinical studies on COVID-19 in china like arbidol, remdesivir and favipiravir. Ribavirin is given intravenous in combination with IFN-α or lopinavir/ritonavir. IFN-α is usually used for hepatitis and inhibit SARS CoV reproduction *invitro*. Lopinavir/ritonavir is given to HIV patients and it shows anti SARS CoV activity *invitro*.

Favipiravir is approved in china on February 15 2020 for treatment of novel influenza it act as an inhibitor for RNA dependent RNA polymerase (RdRp). Remdesivir nucleoside analogue shows antiviral activity by reducing viral load in lung tissue of mice infected with MERS-CoV(10). National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) developing m RNA vaccine with candidate working SARS CoV S protein.(11). It’s a modern technique for curing the disease, but still on trial phases.

**Convalescent plasma therapy.** COVID-19 takes viraemia peaks in the first week of infection in most viral illness. The patient commonly improves a primary immune response by days 10-14, which is followed by virus clearance. Convalescent plasma or immunoglobulin has been used as a last solution to enhance the survival rate of patients
with SARS whose state continued to fade despite treatment with pulsed methylprednisolone. Consequently, it should be more effectual to dispense the convalescent plasma at the primary stage of disease. A meta-analysis by Mair-Jenkins and their team expressed that the death rate was decreased after taking several doses of convalescent plasma in patients with severe acute respiratory infection with no adverse effects or drawback after treatment. Most necessarily, the recent guidelines highlighted that systematic corticosteroids should not be given routinely for the treatment of COVID-19. But, the convalescent plasma therapy which was used in patients who suffered from viral infections was cured without any severe adverse effect. Consequently it might be more worthwhile to test safety and efficacy of convalescent plasma transfusion in SARS-CoV-2-infected patients (12). Biotherapeutics use passive immunotherapy for viral infection such as monoclonal antibodies. The potential of monoclonal antibodies against SARS-CoV and MERS-CoV corona virus are in knowledge is used on COVID-19. Different monoclonal antibody has greater anti-viral activity which is used for the treatment and prevention of viral escape (13).

Preventive measures which has been used as masks, hand hygiene practices, social distancing, contact history, and quarantines is a major ways to reduce transmission. No specific antiviral treatment has approves to reduce effectively; hence, infected people can follow the instructions of doctors in COVID 19 treatment centers. (14)

**Discussions**

COVID-19 lockdown the whole world, researchers have no successful tool to cure this syndrome. Here we collect the information of different diagnosis and cure methods that are being developed recently. In this review article we compare all the diagnosis methods which will help the researchers to develop a new and fast method of diagnosis. Antigen ELISA will give fast result to find out the infected person in short time to start treatment and prevent transmission. Early stage diagnosis is very essential to stop the chain of virus and to control human to human transmission.

It also includes curative/treatment methods that are reported now a day. A combination of different medicine as shown here in this review may give a fast result to fight against the disease. If we isolate the antibodies that are produced after infection from the recovered patients and develop it artificially gives a better treatment to COVID-19. These artificial antibodies cannot allow the virus to be mutant.

**References**

1. Michael Chung, Adam Bernheim, Xueyan Mei, Ning Zhang, Mingqian Huang, Xianjun Zeng, Jiufa Cui, Wenjian Xu, Yang Yang, Zahi A. Fayad, Adam Jacobi, Kunwei Li, Shaolin Li, Hong Shan: CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)., RSNA Vol. 295, No. 1.

2. Yishan Wang, Hanyujie Kang, Xuefeng Liu, Zhaohui Tong: Combination Of Rt-Qpcr Testing And Clinical Features For Diagnosis Of Covid-19 Facilitates Management Of Sars-Cov-2 Outbreak., Journal Of Medical Virology, Https://Doi.Org/10.1002/Jmv.257225 February 2020

3. Zi Yue Zu, MSc; Meng Di Jiang, MSc; Peng Peng Xu, MSc; Wen Chen, MD; Qian Qian Ni, PhD; Guang Ming Lu, MD; Long Jiang Zhang, MD, PhD: Coronavirus Disease 2019 (COVID-19): A Perspective from China., RSNA https://doi.org/10.1148/radiol.2020200490, Feb 21 2020
4. Nisreen M.A. Okba, Marcel A. Müller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lammers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B. E. M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, & Bart L. Haagmans: SARS-CoV-2 specific antibody responses in COVID-19 patients, medRxiv, https://doi.org/10.1101/2020.03.18.20038059

5. Jeffrey S. Kahn, MD, PhD, and Kenneth McIntosh: History and Recent Advances in Coronavirus Discovery. The Pediatric Infectious Disease Journal• Volume 24, Number 11, November 2005. DOI: 10.1097/01.inf.0000188166.17324.60

6. Anthony R. Fehr and Stanley Perlman: Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods Mol Biol. 2015; 1282: 1–23. doi:10.1007/978-1-4939-2438-7_1.

7. Hodler, J.; von Schulthess, G. K.; Zollikofer, C. L. (2007). Diseases of the Heart, Chest & Breast: Diagnostic Imaging and Interventional Techniques. Berlin/Heidelberg: Springer.p. 95. ISBN 9788847006331.

8. M. Infante, R.F. Lutman, S. Imparato, M. Di Rocco, G.L. Ceresoli, V. Torri, E. Morenghi, F. Minuti, S. Cavuto, E. Bottoni, F. Inzirillo, U. Cariboni, V. Errico, M.A. Incarbone, G. Ferraroli, G. Brambilla, M. Alloisio And G. Ravasi: Differential Diagnosis And Management Of Focal Ground-Glass Opacities. European Respiratory Journal 2009 33: 821-827; DOI: 10.1183/09031936.00047908

9. Jianjun Gao, Zhenxue Tian, Xu Yang: Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy In Treatment Of Covid-19 Associated Pneumonia In Clinical Studies. Bioscience Trends Advance Publication Doi: 10.5582/Bst.2020.01047

10. Liying Dong, Shasha Hu, Jianjun Gao: Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012

11. Kuldeep Dhama, Khan Sharun, Ruchi Tiwari, Maryam Dadar, Yashpal Singh Malik, Karam Pal Singh & Wanpen Chaicumpa.; COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2020.1735227

12. Long Chen, Jing Xiong, Lei Bao, *Yuan Shi: Convalescent plasma as a potential therapy for COVID-19.THE LANCET Infectious Diseases. February 27, 2020, https://doi.org/10.1016/S1473-3099 (20)30141-9

13. Balamurugan Shanmugaraj, Konlavat Siriwattananon, Kittikuhn Wangkanont, Waranyoo Phoolcharoen; Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020;38:10-18 DOI 10.12932/AP.200220-0773

14. Sasmita Poudel Adhikari, Sha Meng, Yu-Ju Wu, Yu-Ping Mao, Rui-Xue Ye, Qing-Zhi Wang, Chang Sun, Sean Sylvia, Scott Rozelle, Hein Raat and Huan Zhou.; Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty (2020) 9:29 https://doi.org/10.1186/s40249-020-00646-x